First-in-Human Phase 1 Studies in Oncology: The New Challenge for Investigative Sites

per Salzberg, Marc
Publicat 2012

ACTR-24. THE ESTIMATED LONG-TERM SURVIVAL BENEFIT OF ADDING TTFIELDS TO THE STANDARD OF CARE FOR GLIOBLASTOMA PATIENTS

per Guzauskas, Gregory, Salzberg, Marc, Wang, Bruce
Publicat a Neuro Oncol (2017)

Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients

per Guzauskas, Gregory F, Salzberg, Marc, Wang, Bruce CM
Publicat a CNS Oncol (2018)

Development of a personalized cellular ex-vivo cbl-b silencing cancer immunotherapy

per Lametschwandtner, Guenther, Loibner, Hans, Sachet, Monika, Hayden, Hubert, Hassler, Michaela, Schuster, Manfred, Salzberg, Marc, Triozzi, Pierre, Friedl, Josef
Publicat a J Immunother Cancer (2014)

Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours

per Fiedler, Walter, Stoeger, Herbert, Perotti, Antonella, Gastl, Guenther, Weidmann, Jens, Dietrich, Bruno, Baumeister, Hans, Danielczyk, Antje, Goletz, Steffen, Salzberg, Marc, De Dosso, Sara
Publicat a ESMO Open (2018)

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas

per Fiedler, Walter, Cresta, Sara, Schulze-Bergkamen, Henning, De Dosso, Sara, Weidmann, Jens, Tessari, Anna, Baumeister, Hans, Danielczyk, Antje, Dietrich, Bruno, Goletz, Steffen, Zurlo, Alfredo, Salzberg, Marc, Sessa, Cristiana, Gianni, Luca
Publicat a ESMO Open (2018)

Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors

per Kirson, Eilon D., Dbalý, Vladimír, Tovaryš, František, Vymazal, Josef, Soustiel, Jean F., Itzhaki, Aviran, Mordechovich, Daniel, Steinberg-Shapira, Shirley, Gurvich, Zoya, Schneiderman, Rosa, Wasserman, Yoram, Salzberg, Marc, Ryffel, Bernhard, Goldsher, Dorit, Dekel, Erez, Palti, Yoram
Publicat 2007